Cargando…

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia

Detalles Bibliográficos
Autores principales:	Murray, Heather C., Enjeti, Anoop K., Kahl, Richard G. S., Flanagan, Hayley M., Sillar, Jonathan, Skerrett-Byrne, David A., Al Mazi, Juhura G., Au, Gough G., de Bock, Charles E., Evans, Kathryn, Smith, Nathan D., Anderson, Amanda, Nixon, Brett, Lock, Richard B., Larsen, Martin R., Verrills, Nicole M., Dun, Matthew D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179851/ https://www.ncbi.nlm.nih.gov/pubmed/33067575 http://dx.doi.org/10.1038/s41375-020-01050-y

Ejemplares similares

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
por: Smith, Amanda M., et al.
Publicado: (2016)

Shwachman–Bodian–Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia
por: Dun, Matthew D., et al.
Publicado: (2020)

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
por: Staudt, Dilana, et al.
Publicado: (2018)

Targeting Apoptotic Pathways in Acute Myeloid Leukaemia
por: Sillar, Jonathan R., et al.
Publicado: (2019)

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia
por: Murray, Heather C., et al.
Publicado: (2023)

A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia
por: Enjeti, Anoop K., et al.
Publicado: (2016)

Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection
por: Staudt, Dilana E., et al.
Publicado: (2022)

Correction to: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection
por: Staudt, Dilana E., et al.
Publicado: (2023)

Cell‐Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer
por: Almazi, Juhura G., et al.
Publicado: (2018)

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S, et al.
Publicado: (2018)

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S., et al.
Publicado: (2018)

Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors
por: Cucchi, David G. J., et al.
Publicado: (2021)

Reactive Oxygen Species in Acute Lymphoblastic Leukaemia: Reducing Radicals to Refine Responses
por: Mannan, Abdul, et al.
Publicado: (2021)

scTEM-seq: Single-cell analysis of transposable element methylation to link global epigenetic heterogeneity with transcriptional programs
por: Hunt, Kooper V., et al.
Publicado: (2022)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
por: Dokal, Arran, et al.
Publicado: (2023)

Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia
por: Humphries, Sam, et al.
Publicado: (2023)

Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD(+) Acute Myeloid Leukemia
por: Bregante, Javier, et al.
Publicado: (2021)

Role of the prorenin receptor in endometrial cancer cell growth
por: Martin, Jacinta H., et al.
Publicado: (2022)

Systematic Synergy of Glucose and GLP-1 to Stimulate Insulin Secretion Revealed by Quantitative Phosphoproteomics
por: Tang, Jia-shu, et al.
Publicado: (2017)

The Role of Reactive Oxygen Species in Acute Myeloid Leukaemia
por: Sillar, Jonathan R., et al.
Publicado: (2019)

Combining Mass Spectrometry-Based Phosphoproteomics with a Network-Based Approach to Reveal FLT3-Dependent Mechanisms of Chemoresistance
por: Pugliese, Giusj Monia, et al.
Publicado: (2021)

A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice
por: Mupo, A, et al.
Publicado: (2013)

Ppp2r2a Knockout Mice Reveal That Protein Phosphatase 2A Regulatory Subunit, PP2A-B55α, Is an Essential Regulator of Neuronal and Epidermal Embryonic Development
por: Panicker, Nikita, et al.
Publicado: (2020)

Proteomic Profiling of Mouse Epididymosomes Reveals their Contributions to Post-testicular Sperm Maturation
por: Nixon, Brett, et al.
Publicado: (2019)

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells
por: Roolf, Catrin, et al.
Publicado: (2017)

Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib
por: Ha, You Na, et al.
Publicado: (2020)

PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML
por: Patel, Anand, et al.
Publicado: (2023)

Phosphoproteomics analysis of a clinical Mycobacterium tuberculosis Beijing isolate: expanding the mycobacterial phosphoproteome catalog
por: Fortuin, Suereta, et al.
Publicado: (2015)

Paediatric xanthogranulomatous pyelonephritis with reno-psoas fistula, psoas abscess and migration of renal calculi
por: Harrison, William, et al.
Publicado: (2023)

Measuring pathway database coverage of the phosphoproteome
por: Huckstep, Hannah, et al.
Publicado: (2021)

Evaluation and Properties of the Budding Yeast Phosphoproteome
por: Amoutzias, Grigoris D., et al.
Publicado: (2012)

Characterization of prickle isoform-specific pk (pk1) and pk (sple1) mutations in Drosophila melanogaster
por: Lilienthal, Anthony J, et al.
Publicado: (2022)

Novel Approaches to Target Mutant FLT3 Leukaemia
por: Müller, Jörg P., et al.
Publicado: (2020)

Phosphoproteomic Approaches for Identifying Phosphatase and Kinase Substrates
por: DeMarco, Andrew G., et al.
Publicado: (2023)

Phosphoproteomics Meets Chemical Genetics: Approaches for Global Mapping and Deciphering the Phosphoproteome
por: Jurcik, Jan, et al.
Publicado: (2020)

Flt3 Ligand Regulates Dendritic Cell Development from Flt3(+) Lymphoid and Myeloid-committed Progenitors to Flt3(+) Dendritic Cells In Vivo
por: Karsunky, Holger, et al.
Publicado: (2003)

Phosphoproteomics taken to heart
por: Lundby, Alicia, et al.
Publicado: (2013)

Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy
por: Bond, Danielle R., et al.
Publicado: (2020)

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations
por: Weisberg, Ellen, et al.
Publicado: (2020)

DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
por: Preuer, Kristina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5jvovgeprs1uigp6svldsdcpuv